The DexCom, Inc. (DXCM) Sees Large Growth in Short Interest

The DexCom, Inc. (DXCM) Sees Large Growth in Short Interest

Several equities research analysts have issued reports on the stock. Piper Jaffray Companies reissued an “overweight” rating and issued a $78.00 price target on shares of DexCom in a report on Monday, May 22nd. Jefferies Group LLC lowered their target price on shares of DexCom to $91.00 and set a “buy” rating on the stock in a report on Tuesday, May 9th. B. Riley reissued a “buy” rating and set a $95.00 price objective on shares of DexCom in a report on Sunday, May 7th. Oppenheimer Holdings Inc. set a $98.00 price objective on shares of DexCom and gave the stock a “buy” rating in a report on Wednesday, May 3rd. Finally, Canaccord Genuity cut their price target on shares of DexCom from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 3rd. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $90.44.

DexCom, Inc. (NASDAQ:DXCM) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 9,024,070 shares, an increase of 25.7% from the April 28th total of 7,178,336 shares. Approximately 10.7% of the company’s shares are short sold. Based on an average trading volume of 1,839,366 shares, the short-interest ratio is presently 4.9 days.

In other DexCom news, EVP Andrew K. Balo sold 3,200 shares of DexCom stock in a transaction that occurred on Monday, April 10th. The shares were sold at an average price of $78.19, for a total value of $250,208.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jess Roper sold 2,000 shares of DexCom stock in a transaction that occurred on Wednesday, March 22nd. The shares were sold at an average price of $75.97, for a total transaction of $151,940.00. Following the completion of the sale, the chief financial officer now owns 46,497 shares of the company’s stock, valued at $3,532,377.09. The disclosure for this sale can be found here. Over the last three months, insiders sold 100,312 shares of company stock worth $7,578,606. 2.80% of the stock is currently owned by insiders. Hedge funds and other institutional investors have recently bought and sold shares of the company. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in DexCom during the first quarter valued at $136,000. IFP Advisors Inc raised its stake in DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares in the last quarter. Edmond DE Rothschild Holding S.A. bought a new stake in DexCom during the first quarter valued at about $164,000. Mn Services Vermogensbeheer B.V. raised its stake in DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its position in shares of DexCom by 475.0% in the first quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock valued at $195,000 after buying an additional 1,900 shares during the last quarter.

DexCom (DXCM) opened at 67.68 on Monday. The firm has a 50-day moving average price of $72.24 and a 200 day moving average price of $73.86. DexCom has a 52 week low of $57.68 and a 52 week high of $96.38. The firm’s market capitalization is $5.85 billion. DexCom (NASDAQ:DXCM) last released its earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06. The company had revenue of $142.30 million during the quarter, compared to analysts’ expectations of $143.94 million. DexCom had a negative return on equity of 23.61% and a negative net margin of 10.64%. On average, equities research analysts forecast that DexCom will post ($0.68) earnings per share for the current fiscal year.

DexCom Company Profile Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:DXCM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for DexCom Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DexCom Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment